Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Entero Therapeutics ( (ENTO) ) has shared an announcement.
On September 3, 2025, Entero Therapeutics, Inc. terminated Richard Joel Paolone as Interim Chief Executive Officer and Chairman of the Board without cause, although he remains a director on the Board. The consulting agreement with Mr. Paolone was also terminated, effective immediately. On September 4, 2025, Jason D. Sawyer was appointed as the new Interim Chief Executive Officer. Mr. Sawyer brings extensive experience from the alternative investment industry, having raised significant funds and invested in various sectors, including biotech and fintech, which may influence Entero Therapeutics’ strategic direction.
More about Entero Therapeutics
Average Trading Volume: 1,900,650
Technical Sentiment Signal: Sell
Current Market Cap: $4.29M
For a thorough assessment of ENTO stock, go to TipRanks’ Stock Analysis page.